Evidence map›Paper›PMID 40598690›Full record

ArticleCancer imaging : the official publication of the International Cancer Imaging Society2025

Imaging-derived biomarkers from

Stephan Raad, Ali Al-Fatlawi, C Louise Wise, Christian Fottner, Simin Schadmand-Fischer, Mathias Schreckenberger, Matthias M Weber, Thomas J Musholt, Michael Schroeder, Matthias Miederer

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Stephan RaadNational Center for Tumor Diseases (NCT), NCT/UCC Dresden, A Partnership Between DKFZ, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, and Helmholtz- Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.
Ali Al-FatlawiBiotechnology Center (BIOTEC), Center for Molecular and Cellular Bioengineering, Technische Universität Dresden, Dresden, Germany.
C Louise WiseDepartment of Nuclear Medicine, University Medical Center of the Johannes Gutenberg University, 55131, Mainz, Germany.
Christian FottnerDepartment of Endocrinology, University Medical Center of the Johannes Gutenberg University, 55131, Mainz, Germany.
Simin Schadmand-FischerDepartment of Radiology, University Medical Center of the Johannes Gutenberg University, 55131, Mainz, Germany.
Mathias SchreckenbergerDepartment of Nuclear Medicine, University Medical Center of the Johannes Gutenberg University, 55131, Mainz, Germany.
Matthias M WeberDepartment of Endocrinology, University Medical Center of the Johannes Gutenberg University, 55131, Mainz, Germany.
Thomas J MusholtDepartment of Surgery, University Medical Center of the Johannes Gutenberg University, 55131, Mainz, Germany.
Michael SchroederBiotechnology Center (BIOTEC), Center for Molecular and Cellular Bioengineering, Technische Universität Dresden, Dresden, Germany.
Matthias MiedererNational Center for Tumor Diseases (NCT), NCT/UCC Dresden, A Partnership Between DKFZ, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, and Helmholtz- Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany. matthias.miederer@nct-dresden.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNeuroendocrine tumors have increased in prevalence and diversity in recent years and are often diagnosed at metastatic stages. Compared with nonradioactive systemic treatment with somatostatin analogs, peptide receptor radionuclide therapy (PRRT) has shown superior overall survival benefits for well-differentiated neuroendocrine tumor patients. This study aimed to identify biomarkers from METHODOLOGY: This retrospective study analyzed

resultsThis study included scans from 67 patients with an average age of 67 years. The mean survival time was 46.5 months, with 43% of patients alive or lost to follow-up at the conclusion of data collection. Despite comprehensive analyses, neither volumetric parameters, including total tumor volume and organ-specific tumor volume, nor SUV values (SUVmax and SUVmean) were robust predictors of overall survival. K‒M and Cox regression analyses revealed no significant differences in survival between the high- and low-risk groups for these parameters. Furthermore, radiomics features extracted from liver metastases did not demonstrate significant prognostic value.

conclusionQuantification of

Indexed as

Neuroendocrine TumorsOctreotideOrganometallic CompoundsPositron Emission Tomography Computed TomographyRadiopharmaceuticalsAdultAgedAged, 80 and overBiomarkers, TumorFemaleHumansLiver NeoplasmsMaleMiddle AgedPrognosisRetrospective StudiesBiomarkers, TumorGa(III)-DOTATOClutetium Lu 177 dotatateOctreotideOrganometallic CompoundsRadiopharmaceuticals68Ga-DOTATOC PET/CTNeuroendocrine tumorsOverall survivalPRRTRadiomicsSUVTumor volume

Identifiers

PMID40598690
PMCPMC12211666

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.